mk-2214

Migration, Crosslink

📖

mk-2214

active

wiki page Created: 2026-04-02T07:18:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-mk-2214

📖 Wiki Page

therapeutic1501 wordssynced 2026-04-02

MK-2214

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">mk-2214</th>
</tr>
<tr>
<td class="label">Epitope</td>
<td>Location</td>
</tr>
<tr>
<td class="label">p-tau181</td>
<td>Microtubule binding</td>
</tr>
<tr>
<td class="label">p-tau217</td>
<td>Proline-rich domain</td>
</tr>
<tr>
<td class="label">p-tau231</td>
<td>Proline-rich domain</td>
</tr>
<tr>
<td class="label">p-tau413</td>
<td>N-terminal</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target Epitope</td>
</tr>
<tr>
<td class="label">MK-2214</td>
<td>p-tau413</td>
</tr>
<tr>
<td class="label">Eilanetug (E2814)</td>
<td>MTBR (HVPGG)</td>
</tr>
<tr>
<td class="label">Bepranemab</td>
<td>aa 235-250</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>N-terminus</td>
</tr>
<tr>
<td class="label">Gosuranemab</td>
<td>N-terminal</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>Mid-region</td>
</tr>
<tr>
<td class="label">JNJ-63733657</td>
<td>p-tau217</td>
</tr>
<tr>
<td class="label">Zagotenemab</td>
<td>Conformational</td>
</tr>
</table>

Overview

...

MK-2214

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">mk-2214</th>
</tr>
<tr>
<td class="label">Epitope</td>
<td>Location</td>
</tr>
<tr>
<td class="label">p-tau181</td>
<td>Microtubule binding</td>
</tr>
<tr>
<td class="label">p-tau217</td>
<td>Proline-rich domain</td>
</tr>
<tr>
<td class="label">p-tau231</td>
<td>Proline-rich domain</td>
</tr>
<tr>
<td class="label">p-tau413</td>
<td>N-terminal</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target Epitope</td>
</tr>
<tr>
<td class="label">MK-2214</td>
<td>p-tau413</td>
</tr>
<tr>
<td class="label">Eilanetug (E2814)</td>
<td>MTBR (HVPGG)</td>
</tr>
<tr>
<td class="label">Bepranemab</td>
<td>aa 235-250</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>N-terminus</td>
</tr>
<tr>
<td class="label">Gosuranemab</td>
<td>N-terminal</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>Mid-region</td>
</tr>
<tr>
<td class="label">JNJ-63733657</td>
<td>p-tau217</td>
</tr>
<tr>
<td class="label">Zagotenemab</td>
<td>Conformational</td>
</tr>
</table>

Overview

Mermaid diagram (expand to render)

MK-2214 is an investigational monoclonal antibody therapeutic developed by Merck & Co. (known as MSD outside the United States and Canada) that specifically targets tau protein phosphorylated at threonine 413 (p-tau413). This represents a unique approach in the tau immunotherapy field, focusing on a specific phosphorylation site that has emerged as a promising biomarker for Alzheimer's disease pathology and a potential therapeutic target["@tau2024"][@merck2024].

Scientific Rationale

Tau Phosphorylation in Alzheimer's Disease

The tau protein undergoes extensive post-translational modifications in Alzheimer's disease, with over 40 phosphorylation sites identified[@yoshiyama2013]. Among these, certain phosphorylation sites have emerged as particularly disease-relevant:

Key Phospho-Tau Epitopes:

p-tau181: First discovered AD biomarker, elevated in CSF
p-tau217: Highest diagnostic accuracy for AD, correlates with amyloid
p-tau231: Earliest detectable change, useful for early detection
p-tau413: Associated with advanced pathology, unique targeting opportunity

Why Target p-tau413?

The choice of p-tau413 as a therapeutic target offers several advantages[@tau2024][@ahmad2022]:

Disease specificity: p-tau413 is strongly associated with AD pathology

Pathological relevance: Threonine 413 phosphorylation occurs in NFT-forming tau

Diagnostic correlation: p-tau413 levels correlate with cognitive impairment

Therapeutic potential: Targeting p-tau413 may address advanced tau pathology

Biological significance of Thr413:

Located in the N-terminal region of tau (outside microtubule-binding domain)
Phosphorylation at this site is rare in normal brain
Associated with pathological tau aggregation
Detectable in CSF as a biomarker of disease progression

Comparison with Other Phospho-Tau Targets

Mechanism of Action

Antibody Properties

MK-2214 is designed to selectively bind and neutralize tau species phosphorylated at threonine 413[@tau2024]:

Epitope Specificity:

High affinity for p-tau413
Minimal cross-reactivity with non-phosphorylated tau
Preference for aggregated over monomeric p-tau413

Mechanism of Action:

Selective binding: MK-2214 specifically recognizes tau molecules with phosphorylation at Thr413

Pathological clearance: Fc-mediated uptake by microglia facilitates clearance

Biomarker modulation: May reduce CSF p-tau413 as downstream effect

Propagation prevention: May block cell-to-cell transmission of p-tau413 species

Brain Penetration Considerations

Like all anti-tau antibodies, MK-2214 faces the challenge of crossing the blood-brain barrier[@butchart2019]:

BBB Challenges:

Typical brain:plasma ratios of 0.1-1% for conventional IgG
FcRn-mediated transcytosis provides limited brain exposure
Higher dosing may partially overcome this limitation

Merck's Approach:

Optimized antibody engineering for brain penetration
Dose selection based on preclinical and Phase I data
Monitoring of CSF and plasma biomarkers

Clinical Development

Preclinical Development

The development of MK-2214 required extensive preclinical validation:

Antibody Selection Criteria:

High affinity for p-tau413 with minimal off-target binding
IgG1 isotype for optimal Fc-mediated effector functions
Humanized framework to minimize immunogenicity
Brain penetration properties optimized for CNS target

Preclinical Efficacy Models:

Transgenic mouse models (P301S, rTg4510) with tau pathology
In vitro binding studies using human AD brain tissue
Pharmacodynamic studies showing reduction of p-tau413 species
Safety pharmacology studies supporting advancement to human trials

Phase I Status

MK-2214 is currently in Phase I clinical development[@merck2024]:

Development Timeline:

First-in-human studies initiated (estimated 2023-2024)
Early-phase trials evaluating safety, tolerability, PK/PD
Ongoing as of 2024

Phase I Objectives:

Assess safety and tolerability in healthy volunteers and AD patients
Determine pharmacokinetic properties
Evaluate target engagement biomarkers
Establish optimal dosing for future trials

Clinical Trial Design Considerations

Anti-tau antibody trials face unique challenges[@bittlinger2021][@cummings2024]:

Patient Selection:

Early AD (MCI due to AD or mild dementia)
Confirmed tau pathology (via PET or CSF biomarkers)
Amyloid-positive status (for combination with anti-amyloid)

Endpoints:

Cognitive measures: CDR-SB, iADRS, ADAS-Cog
Biomarker endpoints: tau PET, CSF p-tau413
Safety: ARIA monitoring (less relevant than anti-amyloid)

Comparison with Other Anti-Tau Antibodies

The anti-tau immunotherapy field has multiple programs targeting different epitopes[@bittlinger2021][@cummings2024]:

Unique Features of MK-2214

Phospho-site specificity: Targets a specific phosphorylated residue rather than total tau or conformational epitopes

N-terminal targeting: p-tau413 is in the N-terminal region, different from mid-domain targets

Company backing: Merck's neuroscience program provides substantial resources

Merck's Tau Pipeline Strategy

Broader Portfolio

Merck has been developing multiple approaches to Alzheimer's disease beyond MK-2214[@merck2024]:

Related Programs:

Anti-amyloid antibodies
BACE inhibitors (discontinued)
Tau-targeted approaches
Neuroprotective agents

Strategic Position:

Focus on biomarker-guided patient selection
Emphasis on early disease stages
Combination therapy approach

Comparison with Industry Trends

The tau immunotherapy field has faced significant challenges[@cummings2024]:

Field-Wide Issues:

Multiple high-profile failures (gosuranemab, semorinemab, tilavonemab, zagotenemab)
Brain penetration limitations
Late-stage patient enrollment
Biomarker-clinical disconnect

Potential Advantages of p-tau413 Approach:

More disease-specific targeting
Earlier biomarker changes
May address propagating species

Biomarker Context

p-tau413 as a Biomarker

While primarily a therapeutic target, p-tau413 also serves as a biomarker[@blennow2022][@palmqvist2020]:

CSF Biomarker Properties:

Elevated in AD vs. controls
Correlates with tau PET burden
Tracks disease progression
Potentially responds to therapy

Relationship to Other Biomarkers:

Correlates with p-tau181 and p-tau217
More specific for AD than total tau
Complements amyloid and neurodegeneration markers

Monitoring Target Engagement

For anti-tau therapeutics, biomarker monitoring is critical[@zetterberg2019]:

Expected Biomarker Changes:

Plasma p-tau413: May increase (antibody-bound release)
CSF p-tau413: May decrease (reduced pathology)
Tau PET: May slow accumulation

Challenges:

Complex biomarker dynamics
Limited validation for p-tau413
Need for standardized assays

Therapeutic Implications

Potential Patient Population

MK-2214 would be indicated for:

Early AD patients: MCI due to AD or mild dementia

Tau-positive by biomarkers: Confirmed via PET or CSF

Amyloid-positive: Likely combined with anti-amyloid therapy

Combination Therapy Potential

Given the complexity of AD pathology, combination approaches are likely[@cummings2024]:

Rationale for Combination:

Anti-amyloid + anti-tau may provide synergistic effects
Addresses multiple pathological domains
May improve clinical outcomes

Practical Considerations:

Increased complexity of trial design
Safety monitoring for multiple agents
Regulatory pathway for combinations

Current Status and Future Directions

Development Timeline

As of 2024, MK-2214 remains in Phase I development[@merck2024]:

Near-term Milestones:

Completion of Phase I studies
Decision on Phase II/III advancement
Publication of Phase I data

Long-term Outlook:

Dependent on Phase I results
May require 3-5 years for potential approval
Competitive with other anti-tau programs

Challenges and Opportunities

Challenges:

Demonstrating clear efficacy in a crowded field
Achieving adequate brain penetration
Selecting appropriate patient population
Competing with anti-amyloid therapies

Opportunities:

p-tau413 targeting is unique in the field
Merck's resources and experience
Growing understanding of tau biology

Cross-Links

[Tau Protein](/proteins/tau)
[Phosphorylated Tau Biomarkers](/biomarkers/p-tau-181)
[Anti-Tau Immunotherapies](/therapeutics/anti-tau-immunotherapies)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Tau PET Imaging](/diagnostics/tau-pet)
[Merck](/companies/merck)

References

[Merck tau pipeline (2024)](https://www.merck.com/)

[Tau phosphorylation as therapeutic target (2024)](https://pubmed.ncbi.nlm.nih.gov/38563667/)

[Blennow et al., CSF biomarkers for AD (2022)](https://pubmed.ncbi.nlm.nih.gov/35809012/)

[Zetterberg et al., Neurofilament light chain (2019)](https://pubmed.ncbi.nlm.nih.gov/31553469/)

[Palmqvist et al., Plasma p-tau217 for AD (2020)](https://pubmed.ncbi.nlm.nih.gov/33206061/)

[Jack et al., NIA-AA framework (2020)](https://pubmed.ncbi.nlm.nih.gov/32090487/)

[Cummings et al., AD drug development pipeline 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Bittlinger et al., Anti-tau antibody trials (2021)](https://pubmed.ncbi.nlm.nih.gov/34226711/)

[Sigurdsson EM, Tau immunotherapy (2016)](https://pubmed.ncbi.nlm.nih.gov/26541328/)

[Sofruenti et al., Passive immunotherapy targeting tau (2019)](https://pubmed.ncbi.nlm.nih.gov/31177226/)

[Butchart et al., Tau antibody delivery to brain (2019)](https://pubmed.ncbi.nlm.nih.gov/31278167/)

[Kolb et al., Human antibody engineering (2017)](https://pubmed.ncbi.nlm.nih.gov/28071982/)

[Yoshiyama et al., Tau pathology in AD (2013)](https://pubmed.ncbi.nlm.nih.gov/23746536/)

[Moraru et al., Tau PET imaging (2019)](https://pubmed.ncbi.nlm.nih.gov/31126273/)

[Wu et al., Tau oligomers as pathogenic species (2020)](https://pubmed.ncbi.nlm.nih.gov/32251391/)

[Choi et al., Anti-tau conformer antibodies (2022)](https://pubmed.ncbi.nlm.nih.gov/35476528/)

[Alders et al., Phospho-tau antibodies (2021)](https://pubmed.ncbi.nlm.nih.gov/34054067/)

[Schofield et al., Tau phosphorylation sites (2022)](https://pubmed.ncbi.nlm.nih.gov/35098543/)

[Garringer et al., Conformation-specific tau antibodies (2019)](https://pubmed.ncbi.nlm.nih.gov/31272475/)

[Maldonado et al., Tau passive immunotherapy (2021)](https://pubmed.ncbi.nlm.nih.gov/34083092/)

[Ahmad et al., Tau phosphorylation at threonine 413 (2022)](https://pubmed.ncbi.nlm.nih.gov/35099876/)

Pathway Diagram

The following diagram shows the key molecular relationships involving mk-2214 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

therapeutics-mk-2214

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-mk-2214
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-dedb5412fc49
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-mk-2214'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

10%

Debates

0

Incoming

2

Outgoing

8

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

mk-2214

MK-2214

Overview

MK-2214

Overview

Scientific Rationale

Tau Phosphorylation in Alzheimer's Disease

Why Target p-tau413?

Comparison with Other Phospho-Tau Targets

Mechanism of Action

Antibody Properties

Brain Penetration Considerations

Clinical Development

Preclinical Development

Phase I Status

Clinical Trial Design Considerations

Comparison with Other Anti-Tau Antibodies

Unique Features of MK-2214

Merck's Tau Pipeline Strategy

Broader Portfolio

Comparison with Industry Trends

Biomarker Context

p-tau413 as a Biomarker

Monitoring Target Engagement

Therapeutic Implications

Potential Patient Population

Combination Therapy Potential

Current Status and Future Directions

Development Timeline

Challenges and Opportunities

Company Information

Cross-Links

See Also

References

Pathway Diagram

💬 Discussion